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Abstract
This article presents the case of a 35 year-old male with long QT syndrome (LQTS) who
suffered from sudden cardiac arrest. Even though asymptomatic LQTS had been diagnosed,
the patient had not undergone any medical treatment. His two daughters, aged four and seven,
were also diagnosed with LQTS. A new, previously unknown, mutation of the SCN5A gene
has been found in the family. The older daughter died suddenly before implantable cardioverter-
defibrillator (ICD) implantation, but the father and the younger daughter have been implanted
with ICDs. (Cardiol J 2013; 20, 1: 78–82)
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Introduction
The long QT syndrome (LQTS), apart from QT
interval > 440 ms at basal ECG, is characterized
by a higher risk of polymorphic ventricular tachy-
cardia of torsade de pointes type and sudden cardiac
death (SCD). The cause of LQTS is abnormalities
of cardiac ion channels (sodium and potassium) de-
termined genetically or acquired in another way (for
example by drugs). The diagnosis of LQTS is made
on the basis of ECG findings and family interview.
The first manifestation of congenital LQTS can oc-
cur as a syncope or sudden cardiac arrest (SCA).
This article presents the case of a patient who
had suffered from LQTS and experienced SCA. In
the case of one of the patient’s daughters, SCD oc-
curred. It is noteworthy that an unknown mutation
of SCN5A gene was found in the family.
Case report
The patient is a 35 year-old previously healthy
male who was admitted to hospital after a SCA epi-
sode during ventricular fibrillation (VF). His past
medical history was unremarkable. The SCA caused
by VF occurred during a soccer match. The patient
was successfully reanimated by an emergency medi-
cal team with several successive defibrillation
shocks. In the following days of hospitalization,
a prolonged QT interval up to 566 ms at basal ECG
was observed (Fig. 1). The dose of nonselective
beta-blocker (propranolol), administered to the pa-
tient, was increased up to the maximum. Despite
treatment, the patient suffered from multiple ar-
rhythmia recurrences — ventricular tachycardia
often degenerating into VF. Therefore, right ven-
tricular pacing was used at a frequency of 100/min.
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Simultaneously, a decrease in beta-blocker dose
was implemented. No arrhythmia recurrences were
observed by the tenth day. The patient was implant-
ed with a cardioverter-defibrillator (ICD) with the
function of DDD stimulation. Initially, the stimula-
tion was 100/min, but over the following days this
was slowly decreased.
Having interviewed the patient’s relatives, it
turned out that prolongation of QT interval had been
observed at the patient’s previous basal ECG. At that
time, no treatment had been implemented. The pa-
tient was an active sportsman with no history of syn-
copes. The patient’s younger daughter aged four was
noticed to have a borderline QT interval (Fig. 2) with
no disease symptoms, whereas his older daughter
aged seven was diagnosed with LQTS (Fig. 3) and
beta-blocker treatment was implemented. She had
fainted only once prior to the diagnosis of LQTS.
Molecular testing of KCNQ1, KCNH2, SCN5A,
KCNE1 and KCNE2 genes was performed, and
K1477N mutation in the SCN5A gene was found in
the described patient and his two children. This
gene variant had not been previously described as
a mutation causing the long type 3 QT syndrome.
The lack of data in the literature and the lack of
a population control for this part of the SCN5A gene
made it impossible to state clearly whether the
LQTS syndrome was caused by the said change.
Figure 1. Resting ECG registration on the first day of hospitalization; 50 mm/s; major QTc prolongation
(QTc calculated by Bazett’s formula = 566 ms).
Figure 2. The four year-old daughter’s ECG registration; 50 mm/s; QTc interval = 457 ms.
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Taking into consideration the episode of SCA in the
described patient, his two daughters were advised
to report to the Tertiary Referral Pediatric Hospi-
tal immediately for genetic examination. Several
months after obtaining the results of the genetic
examination, the older patient’s daughter sudden-
ly died at home. The younger one was implanted
with an ICD in the following months.
During the routine follow up (three years)
there has been no cardioverter discharge and in the
cardioverter memory no ventricular arrhythmias
have been noted.
Discussion
The diagnostic criteria of LQTS are known in
the form of a point scale, which includes electro-
cardiographic findings, clinical symptoms, and fami-
ly history [1]. However, it is well-known that the
sensitivity of such criteria is very low, so genetic
testing is considered to be the most sensitive meth-
od of diagnosing LQTS [2].
There are some correlations between genotype
and clinical manifestation of LQTS [3]. The differ-
ences relate to the age at which the first manifes-
tation of the disease occurs, trigger factors, and the
method of treatment. It is worth noting that the
LQT3 type is associated with mutations in the so-
dium channel gene. Unlike LQT1 and LQT2, LQT3
can lead to life-threatening ventricular arrhythmias,
mainly during sleep or at rest. Moreover, it is chara-
cterized as being of poor prognosis and limited effi-
cacy of beta-blockers therapy [3]. A higher efficacy
in treating LQT3 is obtained by combining beta-
-blockers with mexiletine. However, such treat-
ment is not equally effective in all patients [4]. The
manifestations described above are typical clinical
manifestations of LQT3. Nevertheless, in some
cases, the symptoms observed show features that
are typical to two different types of LQTS. In our
patient, SCA occurred while doing exercise, some-
thing that is characteristic of LQT1. On the other
hand, the administration of high doses of beta-block-
er showed no response. It can even be stated that
the increase of the dose caused more frequent poly-
morphic ventricular tachycardias. Right ventricular
pacing at a high frequency (100/min) resulted in
regression of arrhythmia recurrences. This is
a characteristic image of LQT3, where the frequen-
cy of arrhythmia relapses treated by beta-blockers
reaches 50% [3].
Despite still developing molecular diagnostics, it
should be noted that molecular testing has shown
a low penetration in LQTS (around 25%) [5], which
frequently results in an asymptomatic course of the
disease. Moreover, the fact that many genetic chang-
es responsible for the incidence of LQTS remain un-
recognized makes the diagnosis even more difficult.
In the described case report, molecular test-
ing showed the presence of a new genetic change
in the SCN5A gene not related to LQTS so far. Having
taken into account the particularly malignant course
of the LQTS (SCA in the father’s case and SCD in
the daughter’s case), further research aimed at ex-
plaining the pathogenic role of the described muta-
tion is of vital importance.
Figure 3. The seven year-old daughter’s ECG registration; 50 mm/s; QTc interval = 561 ms.
81
Beata Uziębło-Życzkowska et al., LQTS connected with so far unknown mutation
www.cardiologyjournal.org
Regarding genetic testing, patient genomic
DNA was analyzed for mutations in all translated
exons, including splice sites and adjacent regions,
of the five major LQTS-susceptibility genes using
a polymerase chain reaction and denaturing high-
performance liquid chromatography, followed by
DNA sequencing. As a result, K1477N mutation in
the SCN5A gene was found in the patient and his
two children. No other presumed mutation or high
risk single nucleotide polymorphisms have been
found in the proband. It must be noted, however,
that nearly 2% of healthy Caucasians and 5% of
healthy non-Caucasians host rare missense SCN5A
variants, which makes the proper interpretation of
genetic test results a real challenge [6].
Heterologous expression studies of ion chan-
nel variants allow the in vitro assessment as to
whether the mutation confers a perturbed pheno-
type. However, due to methodological constraints,
the method is not suitable for regular clinical test-
ing, and to date less than 20% of all published LQTS-
-causing mutations have been characterized func-
tionally [7, 8].
In our case, in vitro evaluation of K1477N has
not been done since this research tool was not avail-
able to the authors. On the other hand, the number
of family members available for testing was too low
to perform a co-segregation study.
It is clear that knowledge about the specific
gene-encoded regions is a vital determinant of the
likelihood of pathogenicity. In our case, delibera-
tions on a possible influence of K1477N variant on
SCN5A-encoded NaV1.5 sodium channel must be
based on the location of the mutation within the
gene, and a review of all published data on SCN5A-
-gene variants. The K1477N mutation is located in
an interdomain linker (IDL) between domains DIII
and DIV, which is known to be important for cur-
rent inactivation and to be involved in determining
a LQT3 phenotype [7]. In the paper by Kapa et al.
[8], of 28 SCN5A mutations, only four were found
in IDL DIII/DIV, one of them being a rare control.
On the other hand, in an international compen-
dium of mutations in the SCN5A gene in patients
referred for Brugada syndrome genetic testing, only
six mutations were placed in IDL DIII/DIV [9]. In-
terestingly, Grant et al. [10] described a family with
sudden death and features resembling LQTS, Bru-
gada syndrome, and conduction system disease at
the same time. In this family, K1500del, also locat-
ed in the intracellular linker DIII-DIV, accounted
for the complex phenotype. To the best of our
knowledge, the K1477N mutation was absent from
all previously published reports and all published
databases listing the SCN5A channel common poly-
morphisms.
In order to treat patients suffering from LQTS,
beta-blockers are firstly used. Nevertheless, as stat-
ed above, their efficacy in LQT3 is questionable.
Despite beta-blocker therapy, the risk of death
among patients from the high-risk group (under-
stood as patients after SCA or syncope episodes) is
up to 14% within five years [11]. Therefore, in the
case of such patients, the only way of minimizing
SCA is the implantation of a ICD [12].
The evaluation of SCA in asymptomatic pa-
tients still remains a challenge. The indication to
implant an ICD within primary prevention is the
controversial subject of much discussion. The fol-
lowing are considered to be the main SCD factors
in LQT3 [13]: returning syncopes, beta-blockers
intolerance, and family history of sudden death or
LQTS. Young age is also considered to be a factor
causing the risk of dangerous arrhythmias in LQTS
[14]. One of the most difficult decisions is the im-
plantation of an ICD in children. The long future
lifespan and hence the large number of procedures
of ICD and electrode replacement are a great bur-
den on the patient. Furthermore, about 20–30% of
ICD discharges are inappropriate. This can influ-
ence young people’s minds and can lead to a dra-
matic deterioration of life quality, and ultimately to
suicide [15]. On the other hand, taking into account
the serious consequences of delaying the decision
of invasive therapy (the death of the patient’s
daughter prior to the final decision as to ICD im-
plantation) this method should be seriously consid-
ered and used in the treatment of both adults and
children.
Conclusions
In our case, we observed the congenital form
of LQTS caused by a previously unknown SCN5A
gene mutation. This case report confirms that this
genetic mutation might be life-threatening. Thus,
our findings accord with those of other authors who
have reported that the presence of a mutation in the
SCN5A gene requires the implantation of an ICD,
even in asymptomatic patients [16].
Taking into account that the interdomain link-
er DIII-DIV may have different biophysical proper-
ties than those of other IDLs, such mutations are
more likely to be deleterious. The higher certainty
of disease, the more likely it is that a mutation is
disease-causing. We therefore suppose that K1477N
could be considered a possible LQTS-causative
mutation. Certainly, independent validations of
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pathogenicity with in vitro functional analysis are
needed before this can be upgraded to the list of
highly probable deleterious mutations.
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